On Friday, P4ADNow launched a campaign addressing four members of the House of Representatives — Reps. Hudson, Peters, Schrader, and Valadao — who are threatening to block Medicare negotiation bill H.R. 3. Along with digital ads and grassroots advocacy, the campaign includes video ads featuring Therese Ball, a multiple sclerosis patient and retired nurse. P4ADNow’s campaign directed towards the 117th Congress, first launched in May, also expanded this week to add two more House districts and highlights blood cancer patient Steven Hadfield’s story in new ads. — (The Washington Post)
2.The People Are Behind You
P4ADNow also launched a campaign this week encouraging two members of the Senate Finance Committee — Senators Carper and Menendez — to push for a bill that includes Medicare negotiation. “The medications I need to live are priced at over $7,000 every month,” Therese says in the video ads. “I can’t afford these prices. I had to ration and skip doses.” Ads encouraging Senators Bennet and Casey to support the legislation were suspended after both senators reaffirmed their continuedcommitment to fighting for Medicare negotiation in the Senate Finance Committee’s drug pricing bill. — (P4ADNow)
3.The Hidden Hand
P4AD released a new report detailing the often-undisclosed relationships between patient organizations and drug corporations that create conflicts of interest when it comes to drug pricing reforms. The report examines a sample of 15 national patient organizations, four patient assistance charities, and four astroturf groups. “Patients and the public need to know that the pharmaceutical industry’s financial power may influence the public policies for which these organizations advocate, especially on the issue of drug pricing,” the report says. As H.R. 3 and other drug pricing legislation gain momentum in Congress, “policymakers, elected officials, and the news media must be made aware that when these groups act and speak, the influence of Big Pharma money may actually be at work behind the scenes.” — (Politico)
4.Profits Over Patients
A government report found that some prescription drugs with the highest advertising spending were also among those with the highest Medicare expenditures. Drug companies pour billions of dollars each year into advertising concentrated on brand-name drugs with monopoly pricing. It’s no surprise that pharma wants more patients on the most profitable drugs — we must allow Medicare to negotiate lower prices. — (Axios)
5.Case Study: Antiparasitics
A new analysis revealed that skyrocketing prices of antiparasitic treatments were associated with fewer patients taking the drugs they needed. Between 2010 and 2018, the average price of drugs recommended for treating pinworm, a parasitic infection, increased from $14.81 to $930. At the same time, the percentage of patients with a pinworm diagnosis receiving the recommended treatment dropped from 81 percent to 28 percent. Too many patients are sacrificing their quality of care due to high drug prices. We deserve better than this. — (Healio)
Price hikes are coming up fast, and we’re furious that Big Pharma’s bad behavior has lasted way longer than this movie franchise. Welcome to the Week in Review.
The Principal Principle: Medicare Negotiation
On Tuesday, Senate Finance Committee Chairman Ron Wyden released his Principles for Drug Pricing Reform, and topping the list is Medicare negotiation. The senator also calls for extending drug pricing reforms to all Americans and including provisions to incentivize innovation. We are grateful for Chairman Wyden’s leadership and look forward to working with him and the Senate Finance Committee to expand on these principles in legislation that will bring relief to millions of patients. — (The Hill)
2. Don’t Be Fooled
P4ADNow released a new video this week exposing how Big Pharma’s focus on lowering out-of-pocket prescription drug costs will only shift the way Americans pay for pharma’s high prices. It’s clear that Congress must focus on legislation like H.R. 3 that lowers list prices set by Big Pharma to bring patients real relief. “If we take less money out of this pocket without lowering list prices, pharma will take more money out of that pocket by way of higher premiums and taxes,” the animated video says. “With H.R. 3, patients keep more money in their pockets.” — (P4ADNow)
3.Path Emerges For Drug Price Reform
With a bipartisan infrastructure compromise struck, the path for drug pricing reform is coming into view. House leadership has been clear that they intend to include Medicare negotiation bill H.R. 3 in their spending package, and Senate Finance is busy working on their own comprehensive drug pricing bill for inclusion. Patients stand ready to ensure that the final reconciliation bill includes legislation to allow Medicare to negotiate lower drug prices on behalf of Americans. — (The Washington Post)
4.Aduhelm Spending May Rocket Above NASA
Government spending on Biogen’s new Alzheimer’s drug Aduhelm, which may cost Medicare and Medicare enrollees as much as $29 billion in a single year, could surpass spending on major programs such as NASA and the CDC. With a price tag for each patient of $56,000 a year, Aduhelm will break the bank for taxpayers, employers, insurers, and patients. This week, both employer and insurer groups expressed concern over Aduhelm’s high list price. It’s clear the drug’s outrageous price is a symptom of a broken drug pricing system. Congress must empower Medicare to negotiate lower drug prices. — (The New York Times)
5.Price-Fixing Ploys
Teva Pharmaceuticals will pay $925,0000 to settle a case in Mississippi where the company is accused of conspiring with other drug corporations to fix prices of generic drugs. But that’s not all: Teva is also in the midst of settlement discussions with a number of other states and is facing a separate federal charge for price fixing. Another egregious example of Pharma doing anything to cash in. — (FiercePharma)
Welcome to the Week in Review (a day early, in observance of Juneteenth)
Colorado Stands Up to Big Pharma
In a big win for patients, Colorado Gov. Jared Polis signed into law SB 21-175, a bill that establishes a prescription drug affordability board. Colorado is the third state in the country to establish such a board, the first in the country to have a board with the authority to set upper payment limits, and the first in the country where set rates apply to all insurers. The new prescription drug affordability board, which has overwhelming support from Coloradans, is an important step to protecting patients and standing up to Big Pharma. — (AP)
2.Aduhelm: Medicare Negotiation Poster Child
The pricey new Alzheimer’s drug Aduhelm, which Biogen priced at $56,000, is set to cost taxpayers billions — and underscores exactly why we need Medicare to negotiate drug prices. Big Pharma cannot be allowed to keep dictating drug prices, in this case for an unproven drug, while taxpayers and patients empty their pockets. H.R. 3, the bill in the House to allow Medicare to negotiate lower prices on behalf of Americans, would restore balance to our system so we can get real innovation at prices we can afford. — (The Washington Post)
3.NJ Patients Need Congress To Support H.R. 3
P4ADNow founder David Mitchell penned an op-ed that calls on members of Congress, including Sen. Menendez and Rep. Gottheimer, to stand with New Jersey patients and pass H.R. 3. Mitchell explains the need for Medicare negotiation by highlighting New Jersey patient Lisa Wetzel-Trainor’s story about living with fibromyalgia, PTSD, and ADHD and struggling to afford her $1,000-a-month medication she is prescribed to treat her symptoms. More than 1 million Medicare patients in New Jersey would benefit from Medicare negotiation. “It’s time to act.” — (NJ Herald)
4.?, Maine!
The Maine state house and senate passed Making Health Care Work for Maine, a strong bipartisan package of five bills that stand up to Big Pharma. If signed into law, two of the bills — LD 675 and LD 1117 — will be the first legislation of its kind to protect patients from pharmaceutical price gouging and unjustified price increases. No patient should suffer so pharma can line its pockets. — (P4ADNow)
5.The People Have Spoken
New KFF research confirms that prescription drug prices continue to be a top issue to American voters. Three in 10 Americans report they were unable to take their medication as prescribed because of the price. To bring relief to those patients, nearly nine of 10 Americans favor allowing the government to negotiate with drug companies for a lower price that would apply to both Medicare and private insurance. Pass H.R. 3, Congress! The people have your back! — (KFF)
Bonus?: Patients For Affordable Drugs Founder David Mitchell talks to Healthcare-NOW about the importance of Medicare negotiation, drug pricing and innovation, and the COVID-19 vaccine. — (Healthcare-NOW!)
This week: a new royal baby and a new drug only royalty can afford. Welcome to the Week in Review.
Drug Pricing Poster Child
After the FDA approved Aduhelm, a drug intended to target the disease process of Alzheimer’s, drug maker Biogen set its list price at a staggering $56,000 per year. It’s an outrageous price for a drug that hasn’t even been proven clinically effective yet. At this cost, treatment for even one-third of Alzheimer’s patients would raise U.S. drug spending by about 22 percent. Aduhelm is a poster child for why Medicare should be allowed to negotiate drug prices — our system and patients cannot support unlimited prices. Without Medicare negotiation, we’re going to watch “our system bend, break, buckle under the weight of this kind of drug and this kind of pricing.” — (USA Today)
2.Congress Negotiates Negotiation
Congressional Democrats are continuing to work on legislation to allow Medicare to negotiate lower drug prices. Senate Finance Chair Wyden is drafting a bill that is expected to include negotiation, Senate Majority Leader Schumer is also at work on the issue, and House Democrats are pushing to include H.R. 3 in the next budget reconciliation package. Congress must keep advancing on a path to reform our broken drug pricing system and lower prices for Americans. — (The Hill, The Washington Post)
3.Colorado Makes History
In a huge win for Colorado patients, the state legislature passed a bill that would establish the third prescription drug affordability board in the nation — and the first with the power to set upper payment limits on unaffordable drugs. We are grateful to state lawmakers for standing with Colorado patients and look forward to Gov. Jared Polis’ signature on the bill in the coming weeks! — (The Denver Post)
4. Seniors Pay The Price
A new AARP report found that the prices of 260 commonly used drugs increased by more than double the rate of inflation last year. Drug prices are becoming more and more unsustainable for seniors like Pam Holt, who lives with multiple myeloma and pays thousands of dollars for Revlimid each year, and Lynn Scarfuto, who lives with chronic lymphocytic leukemia. “People cannot afford to make a choice between food or living and taking pills,” Lynn said. — (AARP, MarketWatch, USA Today)
5. Pharma Pours Cash On Lawmakers
New analyses from STAT reveal the broad financial influence that pharma has in Congress and in state legislatures across the country. During the 2020 election cycle, the drug industry made campaign contributions to over two-thirds of Congress and one-third of state lawmakers, totaling about $23 million. Patients can’t match pharma in its outrageous spending funded by constant price hikes, but we are fighting back with our voices and stories — and we will win. — (STAT)
What do AbbVie and UFOs have in common? They’re both under investigation by the U.S. government.
Welcome to the Week in Review.
Take The Lead: Pass H.R. 3
New national and state polls from West Health show just how popular Medicare negotiation is among Americans. Across the country, 81 percent of Americans believe the government should be allowed to negotiate lower drug prices, with similar levels of support in Arizona, Delaware, New Jersey, and West Virginia. It’s settled: Americans demand Medicare negotiation. Congress must pass H.R. 3 now. — (The Hill)
2.Pharma Adds To List Of Offenses
Following last month’s House Oversight and Reform Committee hearingon pharma giant AbbVie’s abusive pricing practices, on Wednesday the Senate Finance Committee launched its own probe into the drug company’s scheme to avoid paying American taxes. In a letter to the CEO of AbbVie, Senate Finance Chair Wyden raised concerns that AbbVie reported a domestic pretax loss of $4.5 billion and a foreign pretax profit of $7.9 billion last year despite generating most of its revenue in the United States. Yet again, pharma shows it’s all too willing to exploit taxpayers and patients, all to maximize its bottom line. — (Reuters)
3.“An Easy Choice That Will Save Lives”
The New Jersey legislature must establish a prescription drug affordability board and lower drug prices for patients across the state, writes Assemblyman John McKeon in an op-ed. Polls show that 43 percent of New Jerseyans have delayed or forgone taking a prescribed medication due to high costs, and 88 percent support drug affordability board legislation. “All across our state working families are struggling to afford life-saving medicine,” McKeon writes. “It’s time to focus on the real problem and bring down drug costs for everyone in New Jersey.” — (The Star-Ledger)
Between the Friends reunion and pharma’s lies about H.R. 3’s impact on innovation, it sure feels like deja vu.Welcome to the Week in Review.
Momentum Grows
This week, 156 House Democrats — 70 percent of the House Democratic Caucus — signed a letter urging the Biden administration to include Medicare negotiation in the American Families Plan. Meanwhile, President Biden doubled down on his support of proposals to lower drug prices in his 2022 budget released Friday. The momentum for passing meaningful reforms clear — Congress, the president, and patients agree that lowering drug prices must be a top priority this year. Together, we’ll fight to get it done. — (The New York Times)
2.Pharma Giant At It Again
Just as the House Oversight and Reform Committee released its reporton the abusive pricing practices of pharma giant AbbVie, the company is helping to bankroll enormous lobbying efforts to block comprehensive drug pricing legislation in Congress. Big Pharma claims its high prices fund innovation, but it’s clear high prices reap enormous profits for the industry — and Big Pharma doesn’t want to see an end to those anytime soon. — (Salon)
3.Negotiation Works
The success of COVID-19 vaccine development and distribution in the United States is a testament to how government investment and price negotiation can rapidly bring patients the drugs we need without sacrificing innovation, according to a new op-ed by Harvard economist Richard Frank and Mark Miller of Arnold Ventures. “Negotiation accompanied by infrastructure and innovation investments can balance both the budget and the need for scientific breakthroughs, making innovative therapies accessible and affordable,” the authors write. “Americans deserve better than what they are currently getting.” — (The Hill)
Captain America has weighed in — drug prices must be lowered. Welcome to the Week in Review.
Dear Congress: Patients Need You To Keep Fighting
Patients For Affordable Drugs Now launched a national campaign this week urging members of Congress in 42 House districts to support H.R. 3, which would allow Medicare to negotiate lower drug prices. The campaign includes video ads featuring patient Marcus LaCour, who lives with type 1 diabetes. “Because insulin is so expensive, I’ve had to skip and ration my doses,” Marcus says in one ad. “We need Congress to keep their promises, and get the job done now.” The campaign comes as the fight for drug pricing heats up, with Big Pharma doing everything it can to fight against much-needed drug pricing reform. The message from patients is clear: Congress must stand with patients instead of with pharma’s special interests. — (Fox Business, Axios)
2.The Price Of Pharma’s Unilateral Pricing Power
During a House Oversight and Reform Committee hearing examining pharma giant AbbVie’s unethical pricing practices, three patient advocates shared their experiences with the impact of the company’s high-priced drugs. “The excessive Humira price forces me to choose every month whether to eat or fill my prescriptions,” Katherine Pepper, who is prescribed Humira injections for psoriatic arthritis, told the committee. “You have the power to change that,” Lynn Scarfuto, who lives with cancer and takes Imbruvica, told the members. — (NBC)
3. H.R. 3 Is Good For Business
A new analysis estimates that Medicare negotiation would save employers $195 billion and workers $61 billion from 2023 to 2029. Nearly 90 percent of small business owners say in a separate poll that drug costs are too high. 85 percent believe Medicare should be allowed to negotiate the prices of costly prescription drugs. H.R. 3 has a broad reach: It will bring patients, employers, and employees relief. — (West Health, Small Business for America’s Future)
4. Patent Abuse Alert
A report from drug patent watchdog I-MAK delves into Merck’s abusive patent practices on its cancer drug Keytruda, which currently has an annual price of over $165,000. The 53 patents Merck has received on the drug have extended Merck’s monopoly pricing period by an additional eight years. During that time, it’s estimated Americans will spend $137 billion on Keytruda. It’s a prime example of how drug companies weaponize a patent system meant to reward innovation and use it to turn billions in profit. — (I-MAK)
5. Patients Take On State Capitols
Patients also made their voices heard in state legislatures this week. In Colorado, patient advocate Kris Garcia shared his story in support of a bill that would establish a prescription drug affordability board. “I had to give up my dream of being a business owner because of how expensive my medications were,” Kris said. The bill was passed out of the House Health and Insurance Committee on a 8-4 vote. Oregon patient advocate Joanna Olson, who takes Eliquis, delivered testimony in support of a bill that would ban collusive “pay-for-delay” deals between drug manufacturers. “Every time I pick up the prescription, I think about leaving without the drug,” Joanna shared. — (P4ADNow)
If Bennifer can be revived, drug prices can be lowered. Welcome to the Week in Review.
“The Time To Act Is Now”
Rep. Peter Welch and P4AD founder David Mitchell penned an op-ed for The Hill that calls on Congress to pass H.R. 3, a bill that would finally let Medicare negotiate for lower drug prices. “Now is the time for Congress to pass legislation that will deliver meaningful relief from high drug prices to the American people,” they write. We can’t keep upholding a system that allows patients to die because they can’t afford the drugs they need. Congress must stand with patients and support H.R. 3. — (The Hill)
2. Maine Fights Pharma Greed Statewide And Nationally
This week, Rep. Jared Golden (ME-02) authored an op-ed in the Bangor Daily News, warning Congress not to fall for Big Pharma’s lies as legislators look to make drugs affordable with bills like H.R. 3. “Big pharmaceutical companies’ greed stands in the way of progress to lower prescription drug prices,” Rep. Golden writes. Earlier in the week, the BDN editorial board praised Maine lawmakers for prioritizing lowering prescription drug prices this session. State legislators are currently considering a sweeping package of bills that would reduce prices for Maine patients. The message in Maine is clear — patients need relief. — (Bangor Daily News Opinion, Bangor Daily News Editorial Board)
3.WV Senators: Patients Need You
In a letter to the editor, West Virginia patient Ashley Suder calls on Senators Joe Manchin and Shelley Moore Capito to support H.R. 3. Ashley lives with lupus and depends on Benlysta, which costs over $35,000 — and figuring out how to afford the drug is a constant battle. Patients, already burdened with the physical and mental toll of living with an illness, shouldn’t also have to fight for affordable medications. For patients like Ashley, we must do better. — (The Charleston Gazette-Mail)
4. A Case Study: Cancer Drugs
Cancer drugs are incredibly expensive, creating an astronomical financial burden on taxpayers. Because many of these drugs lack direct competitors, pharma companies essentially have free rein to dictate prices. Meanwhile, Big Pharma wants cancer patients and families to think high prices are the only way to ensure that new treatments keep coming to market. It’s simply not true. We don’t have to choose between affordable medications and new treatments. — (Fortune)
5. Cracking The Innovation Myth
Big Pharma, desperate to keep its unfettered pricing power, insists that Medicare negotiation bills like H.R. 3 would stifle innovation and prevent patient access to critical new drugs. The truth is, H.R. 3 would allow patients to get the important innovation they need at prices they can afford, and pharma would still remain one of the most profitable industries. Don’t fall for pharma’s bald-faced lie. — (Fast Company)
